26944-48-9

Usage

Uses

Used in Pharmaceutical Industry:
Glibornuride is used as an antidiabetic agent for the treatment of type 2 diabetes mellitus. It helps in controlling blood sugar levels by promoting the release of insulin from the pancreatic beta cells, thus assisting in the regulation of glucose metabolism.
Additionally, Glibornuride has been shown to have potential applications in other areas, such as:
1. Airway Smooth Muscle Relaxation:
Glibornuride is used as a relaxant for airway smooth muscle relaxation. It has been demonstrated to antagonize the relaxant response to the K+ channel opener cromakalim, which can be beneficial in treating conditions related to airway constriction.
2. Lactic Acidosis and Hypoglycemia Management:
Glibornuride is associated with the management of lactic acidosis and hypoglycemia in patients with type 2 diabetes mellitus. By regulating insulin release and glucose metabolism, it can help prevent or mitigate the onset of these complications.

Originator

Glutril,Roche,W. Germany,1972

Manufacturing Process

2.1 grams of 3-endo-aminoborneol hydrochloride and 2.4 grams of O-methylN-p-toluene-sulfonyl-urea are heated at 125°C for 3 hours with 2 ml of dimethylformamide. After cooling, the reaction mixture is stirred with 100 ml of water for 10 minutes, while a pH of 3.5 is maintained by the addition of a few drops of dilute hydrochloric acid. The precipitate is removed by filtration, washed with water and suspended in 100 ml of water. The suspension is dissolved by the addition of 20 ml of 1 N caustic soda. The alkaline solution is extracted with ether, acidified with dilute hydrochloric acid and filtered. The precipitate is washed with water and recrystallized from alcohol/water to yield 1-(p-toluene-sulfonyl)-3-(2-endo-hydroxy-3-endo-bornyl)-urea having a melting point of 193° to 195°C.

Therapeutic Function

Oral hypoglycemic

InChI:InChI=1/C18H26N2O4S/c1-11-5-7-12(8-6-11)25(23,24)20-16(22)19-14-13-9-10-18(4,15(14)21)17(13,2)3/h5-8,13-15,21H,9-10H2,1-4H3,(H2,19,20,22)

Downstream Products

• 41719-61-3 (toluene-4-sulfonyl)-((4S)-7,8,8-trimethyl-(3ac,7ac)-3a,4,5,6,7,7a-hexahydro-4r,7c-methano-benzooxazol-2-yl)-carbamic acid ethyl ester 
• 70-55-3 toluene-4-sulfonamide 
• 613-33-2 (4,4'-dimethyl-1,1'-biphenyl) 
• 103-19-5 di(p-tolyl) disulfide 
• 80-48-8 methyl p-toluene sulfonate 
• 108-88-3 toluene 
• 1888-33-1 N-acetyl-(4-methylbenzene)sulfonamide 
• 41719-63-5 (1R,2R,6S,7S)-(-)-1,10,10-trimethyl-3-oxa-5-azatricyclo[5.2.1.0(2,6)]decan-4-one 

Relevant academic research and scientific papers

USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS

The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R 4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula

Combinations comprising dipeptidylpeptidase-iv inhibitor

The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.